{"url":"https://newsforagent.com/news/2026-11-10/arbutus-profit-shareholder-return","markdown_url":"https://newsforagent.com/news/2026-11-10/arbutus-profit-shareholder-return.md","title":"Arbutus Posts $59.1 Million Profit, Returns $230 Million","headline":"Arbutus Swings to $59.1 Million Profit and Returns $230 Million to Shareholders","description":"Arbutus Biopharma reported $59.1 million in third-quarter net income and returned $230 million to shareholders after its Moderna patent settlement.","section":"Earnings & Results","published_at":"2026-11-10T12:59:08+00:00","modified_at":"2026-11-10T12:59:08+00:00","author":"News Desk","key_takeaways":["Arbutus reported third-quarter 2026 net income of $59.1 million, compared with a $7.7 million loss a year earlier.","The company returned $230 million to shareholders in early October 2026 by buying back 46 million shares at $5.00 each.","Arbutus and Genevant filed new patent lawsuits against Pfizer and BioNTech in Japan and amended a Canadian case."],"companies":[{"name":"Arbutus Biopharma","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0003iuj/arbutus-biopharma","website":"http://arbutusbio.com"},{"name":"BioNTech","is_primary":false,"profile_url":"https://akta.pro/company-profiles/0000j4h/biontech","website":"https://www.biontech.com/int/en/home.html"},{"name":"Moderna","is_primary":false,"profile_url":"https://akta.pro/company-profiles/00004gr/moderna","website":"http://www.modernatx.com"}],"source":{"publisher":"GlobeNewswire","title":"Arbutus Reports Third Quarter 2026 Financial Results and Provides Corporate Update","url":"https://www.globenewswire.com/news-release/2026/11/10/3399371/14025/en/arbutus-reports-third-quarter-2026-financial-results-and-provides-corporate-update.html"},"other_sources":[],"tags":["Earnings & Results","Arbutus Biopharma","BioNTech","Moderna"],"body_markdown":"[Arbutus Biopharma](https://akta.pro/company-profiles/0003iuj/arbutus-biopharma) reported third-quarter 2026 net income of $59.1 million, or $0.30 per basic and diluted share, compared with a net loss of $7.7 million a year earlier, and said it returned $230 million to shareholders in early October 2026. The company announced the results on November 10, 2026, according to [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/10/3399371/14025/en/arbutus-reports-third-quarter-2026-financial-results-and-provides-corporate-update.html).\n\nArbutus is a clinical-stage biopharmaceutical company based in Warminster, Pennsylvania, that develops RNAi and oral PD-L1 therapies aimed at a functional cure for chronic hepatitis B and earns licensing, royalty and litigation income from its delivery technology platforms.\n\n## Arbutus Tender Offer and Patent Suits\n\nThe shareholder return came through a modified Dutch Auction tender offer completed in early October 2026, in which Arbutus bought 46 million common shares for cancellation at $5.00 per share, about 23% of shares outstanding as of September 29, 2026. The offer followed the company's receipt of $178.4 million in July 2026 as its share of a $950 million noncontingent settlement payment from [Moderna](https://akta.pro/company-profiles/00004gr/moderna) and a $67.3 million cash dividend from Genevant in September 2026.\n\nArbutus and Genevant also filed additional lawsuits in Japan against Pfizer Japan Inc. and amended a previously filed Canadian case against Pfizer, [BioNTech](https://akta.pro/company-profiles/0000j4h/biontech) and certain affiliates to add a newly issued LNP patent. The new cases are before the Tokyo District Court and seek permanent injunctions and damages over Japanese Patent No. 5,475,753 and Japanese Patent No. 7,936,499. The Canadian amendment adds claims under Canadian Patent No. 2,767,127.\n\nBioNTech's final quarterly earnings call under co-founders Ugur Sahin and Özlem Türeci highlighted its expanding oncology program, In Vivo reported on November 4, 2026.\n\n## Arbutus Cash and Moderna Settlement Figures\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Arbutus resolved all global patent infringement litigation with Moderna in March 2026 for $2.25 billion, comprising $950 million upfront, paid in July 2026, plus up to $1.3 billion contingent on an appellate ruling. The same records show Arbutus received FDA Fast Track designation for imdusiran (AB-729), its lead RNAi therapeutic for chronic hepatitis B, in April 2026.\n\nCash, cash equivalents and marketable securities stood at $337.5 million as of September 30, 2026, compared with $91.5 million at the end of 2025. Total revenue was $0.3 million for the quarter, down from $0.5 million a year earlier.\n\n## Arbutus Buyback and Earnings History\n\nIn August 2026, AInvest reported that Arbutus announced a $230 million Dutch auction share buyback representing approximately 22% of its market capitalization, funded by proceeds from the Moderna patent settlement. On August 12, 2026, Seeking Alpha reported second-quarter GAAP earnings per share of -$0.03, which missed analyst estimates by $0.01, while revenue of $1.01 million beat expectations by $0.33 million.\n\n## Arbutus FDA Decision and Appellate Ruling\n\nThe FDA lifted the clinical hold on the Investigational New Drug application for AB-101, an oral PD-L1 inhibitor, in October 2026, and Arbutus said it is evaluating next steps for continued development. Expedited oral argument was held at the U.S. Court of Appeals for the Federal Circuit on November 5, 2026, regarding the Moderna appeal, and a decision is forthcoming.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}